Logo image of RVPH

REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Price, Quote, News and Overview

NASDAQ:RVPH - Nasdaq - US76152G1004 - Common Stock - Currency: USD

0.85  +0.03 (+3.66%)

RVPH Quote, Performance and Key Statistics

REVIVA PHARMACEUTICALS HOLDI

NASDAQ:RVPH (6/9/2025, 2:59:16 PM)

0.85

+0.03 (+3.66%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High4.28
52 Week Low0.49
Market Cap39.73M
Shares46.74M
Float41.79M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-12 2025-08-12
IPO10-18 2018-10-18


RVPH short term performance overview.The bars show the price performance of RVPH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40 -50

RVPH long term performance overview.The bars show the price performance of RVPH in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RVPH is 0.85 USD. In the past month the price increased by 0.49%. In the past year, price decreased by -42.95%.

REVIVA PHARMACEUTICALS HOLDI / RVPH Daily stock chart

RVPH Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 56.23 733.33B
JNJ JOHNSON & JOHNSON 15.49 374.66B
NVO NOVO-NORDISK A/S-SPONS ADR 20.97 334.54B
NVS NOVARTIS AG-SPONSORED ADR 14.22 233.46B
AZN ASTRAZENECA PLC-SPONS ADR 16.66 227.31B
MRK MERCK & CO. INC. 10.18 199.07B
PFE PFIZER INC 7.49 136.76B
SNY SANOFI-ADR 11.22 121.46B
BMY BRISTOL-MYERS SQUIBB CO 6.7 100.12B
GSK GSK PLC-SPON ADR 9.23 83.41B
ZTS ZOETIS INC 27.51 73.73B
HLN HALEON PLC-ADR 22.28 49.11B

About RVPH

Company Profile

RVPH logo image Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 14 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Company Info

REVIVA PHARMACEUTICALS HOLDI

10080 N Wolfe Road, Suite Sw3-200

Cupertino CALIFORNIA 95014 US

CEO: Laxminarayan Bhat

Employees: 15

RVPH Company Website

RVPH Investor Relations

Phone: 14085018881

REVIVA PHARMACEUTICALS HOLDI / RVPH FAQ

What is the stock price of REVIVA PHARMACEUTICALS HOLDI today?

The current stock price of RVPH is 0.85 USD. The price increased by 3.66% in the last trading session.


What is the ticker symbol for REVIVA PHARMACEUTICALS HOLDI stock?

The exchange symbol of REVIVA PHARMACEUTICALS HOLDI is RVPH and it is listed on the Nasdaq exchange.


On which exchange is RVPH stock listed?

RVPH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for REVIVA PHARMACEUTICALS HOLDI stock?

12 analysts have analysed RVPH and the average price target is 9.62 USD. This implies a price increase of 1031.43% is expected in the next year compared to the current price of 0.85. Check the REVIVA PHARMACEUTICALS HOLDI stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is REVIVA PHARMACEUTICALS HOLDI worth?

REVIVA PHARMACEUTICALS HOLDI (RVPH) has a market capitalization of 39.73M USD. This makes RVPH a Nano Cap stock.


How many employees does REVIVA PHARMACEUTICALS HOLDI have?

REVIVA PHARMACEUTICALS HOLDI (RVPH) currently has 15 employees.


What are the support and resistance levels for REVIVA PHARMACEUTICALS HOLDI (RVPH) stock?

REVIVA PHARMACEUTICALS HOLDI (RVPH) has a support level at 0.79 and a resistance level at 0.82. Check the full technical report for a detailed analysis of RVPH support and resistance levels.


Should I buy REVIVA PHARMACEUTICALS HOLDI (RVPH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does REVIVA PHARMACEUTICALS HOLDI (RVPH) stock pay dividends?

RVPH does not pay a dividend.


When does REVIVA PHARMACEUTICALS HOLDI (RVPH) report earnings?

REVIVA PHARMACEUTICALS HOLDI (RVPH) will report earnings on 2025-08-12.


What is the Price/Earnings (PE) ratio of REVIVA PHARMACEUTICALS HOLDI (RVPH)?

REVIVA PHARMACEUTICALS HOLDI (RVPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.79).


What is the Short Interest ratio of REVIVA PHARMACEUTICALS HOLDI (RVPH) stock?

The outstanding short interest for REVIVA PHARMACEUTICALS HOLDI (RVPH) is 7.28% of its float. Check the ownership tab for more information on the RVPH short interest.


RVPH Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to RVPH. When comparing the yearly performance of all stocks, RVPH is a bad performer in the overall market: 92.29% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

RVPH Financial Highlights

Over the last trailing twelve months RVPH reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 50.31% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -408.61%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%48%
Sales Q2Q%N/A
EPS 1Y (TTM)50.31%
Revenue 1Y (TTM)N/A

RVPH Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to RVPH. The Buy consensus is the average rating of analysts ratings from 12 analysts.


Ownership
Inst Owners29.39%
Ins Owners10.17%
Short Float %7.28%
Short Ratio4.34
Analysts
Analysts81.67
Price Target9.62 (1031.76%)
EPS Next Y25.8%
Revenue Next YearN/A